14 December 2022
EMA/935216/2022
EMEA/H/C/000281

Public statement

IntronA (interferon alfa-2b)

Withdrawal of the marketing authorisation in the European Union

On 30 November 2021, the European Commission withdrew the marketing authorisation for IntronA (interferon alfa-2b) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Merck Sharp & Dohme B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

IntronA was granted marketing authorisation in the EU on 9 March 2000 for treatment of chronic Hepatitis B, chronic Hepatitis C, hairy cell leukaemia, chronic myelogenous leukaemia, multiple myeloma, follicular lymphoma, carcinoid tumour and malignant melanoma.

The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2005. It was then granted unlimited validity in 2010.

The European Public Assessment Report (EPAR) for IntronA will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union